Form 4: FibroBiologics General Counsel Ruben A. Garcia Receives Stock Options

FibroBiologics' General Counsel, Ruben A. Garcia, was granted stock options for 176,200 shares of common stock on December 27, 2024.

Summary

• Ruben A. Garcia, the General Counsel of FibroBiologics, Inc., received stock options for 176,200 shares of the company's common stock.
• The options were granted on December 27, 2024, with an exercise price of $2.36 per share.
• The options vest over a period of four years, with one-fourth vesting after one year and the remaining three-fourths vesting in 36 equal monthly installments.
• The vesting is contingent upon Mr. Garcia's continuous service with the company.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, which is generally positive for aligning management interests with shareholders. There is no indication of any negative issues.

Positives

• The granting of stock options aligns the interests of the General Counsel with the long-term success of the company.
• The vesting schedule encourages continued service and commitment from Mr. Garcia.

Industry Context

Stock option grants are a common form of compensation for executives and key employees in publicly traded companies, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard practice for incentivizing executives in the biotechnology industry.
• The vesting schedule of one year cliff followed by monthly vesting is a common structure to ensure long term commitment.
• The exercise price of $2.36 is a typical value for a stock option grant.

Stakeholder Impact

• Shareholders may view this as a positive sign of aligning management interests with company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, FibroBiologics, General Counsel, equity compensation, vesting, FBLG, insider trading